The global market for cell and gene therapy tools and reagents is expected to grow from $12 billion in 2025 and is projected to reach $19.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.6% during the forecast period of 2025 to 2030.
Cell and gene therapies (CGTs) utilize cellular or genetic resources to treat or prevent diseases, offering a developing translational technique in precision medicine that has the potential to cure diseases that were previously considered incurable.
The U.S. Food and Drug Administration (FDA), China’s National Medical Products Administration (NMPA), the European Union’s European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) have approved a record 13 novel cell and gene therapies (CGTs), making 2024 a pivotal year for therapeutic advances in human diseases. The first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) therapy, the first magnetic resonance imaging (MRI)-guided intracranial adeno-associated virus (AAV) delivery gene therapy and the first tumor infiltration lymphocyte therapy are a few developments that occurred in 2024. These developments marked the beginning of a whole new phase in the practical application of advances in gene editing and cell technologies.
The growing focus on clinical and commercial activities in the CGT sector is expected to drive the global market for cell and gene therapy tools and reagents.
The application segment covered cancer, rare diseases and other diseases. By end user, the market is divided into pharmaceutical and biotechnology companies, academic research institutes, and clinical laboratories.
The regions covered in this study are North America, Europe, Asia-Pacific and rest of the World (RoW) (which includes the Middle East and Africa and South America), with analysis of the markets in the U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, the rest of Europe, China, Japan, India, South Korea and the rest of Asia-Pacific. The report covers the trends and challenges that affect the market. It includes an analysis of the competitive landscape, with the ranking of leading companies and their market shares. The report also has a dedicated section of company profiles that covers details of leading companies. It analyzes companies’ environmental, social and corporate governance (ESG) initiatives.
Cell and gene therapies (CGTs) utilize cellular or genetic resources to treat or prevent diseases, offering a developing translational technique in precision medicine that has the potential to cure diseases that were previously considered incurable.
The U.S. Food and Drug Administration (FDA), China’s National Medical Products Administration (NMPA), the European Union’s European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) have approved a record 13 novel cell and gene therapies (CGTs), making 2024 a pivotal year for therapeutic advances in human diseases. The first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) therapy, the first magnetic resonance imaging (MRI)-guided intracranial adeno-associated virus (AAV) delivery gene therapy and the first tumor infiltration lymphocyte therapy are a few developments that occurred in 2024. These developments marked the beginning of a whole new phase in the practical application of advances in gene editing and cell technologies.
The growing focus on clinical and commercial activities in the CGT sector is expected to drive the global market for cell and gene therapy tools and reagents.
Report Scope
The report provides an overview of the global market for cell and gene therapy tools and reagents. It includes global revenue ($ millions) for the base year 2024, estimated data for 2025, and forecast data from 2026 through 2030. In this report, the market is segmented based on product type, application and end user. By product type, the market is segmented into vectors, GMP proteins, GMP antibodies, GMP small molecules, bioreactors, multiplex immunoassays, immunoassays, leukapheresis, cell separation, cell expansion, cytokine release syndrome (CRS) monitoring, cryopreservation and media.The application segment covered cancer, rare diseases and other diseases. By end user, the market is divided into pharmaceutical and biotechnology companies, academic research institutes, and clinical laboratories.
The regions covered in this study are North America, Europe, Asia-Pacific and rest of the World (RoW) (which includes the Middle East and Africa and South America), with analysis of the markets in the U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, the rest of Europe, China, Japan, India, South Korea and the rest of Asia-Pacific. The report covers the trends and challenges that affect the market. It includes an analysis of the competitive landscape, with the ranking of leading companies and their market shares. The report also has a dedicated section of company profiles that covers details of leading companies. It analyzes companies’ environmental, social and corporate governance (ESG) initiatives.
The report includes:
- 77 data tables and 55 additional tables
- An overview of the global market for cell and gene therapy tools and reagents
- In-depth analysis of global market trends, featuring historical revenue data for 2022-2025. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
- Evaluation of the current market size and revenue growth prospects specific to the cell and gene therapy tools and reagents market, accompanied by a market share analysis by type, application, end user, and region
- Analysis of current and future demand in the cell and gene therapy tools and reagents market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
- Discussion of the prevalence of infectious disease, metabolic disorders and chronic ailments, along with the recent technological advances, competitive landscape, and the industry value chain
- Analysis of drivers, challenges, and opportunities affecting market growth
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Market share analysis of the key market participants in the industry, along with their research priorities, product portfolios, global rankings and company competitive landscape
- Profiles of major companies within the industry, including Thermo Fisher Scientific Inc., Cytiva (Danaher Corp.), Merck KGaA, Miltenyi Biotec, and Sartorius AG
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in Global Market for Cell and Gene Therapy Tools and Reagents: An ESG Perspective
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- Abcam Ltd.
- Adverum Biotechnologies Inc.
- Akron Biotech
- Bio-Rad Laboratories Inc.
- Bio-Techne
- Cytiva
- Fujifilm Irvine Scientific (Fujifilm Biosciences)
- Merck KGaA
- Miltenyi Biotec
- Proteintech Group Inc.
- Qiagen
- Revvity
- Sartorius AG
- Stemcell Technologies
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2026 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 12 Billion |
| Forecasted Market Value ( USD | $ 19.8 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
